DrugPatentWatch Database Preview
Betrixaban - Generic Drug Details
What are the generic sources for betrixaban and what is the scope of freedom to operate?
Betrixaban
is the generic ingredient in one branded drug marketed by Portola Pharms Inc and is included in one NDA. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.Betrixaban has one hundred and twenty-six patent family members in thirty-one countries.
One supplier is listed for this compound.
Summary for betrixaban
| International Patents: | 126 |
| US Patents: | 10 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 59 |
| Clinical Trials: | 9 |
| Patent Applications: | 117 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | betrixaban at DailyMed |
Recent Clinical Trials for betrixaban
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Portola Pharmaceuticals | Phase 3 |
| Merck Sharp & Dohme Corp. | Phase 2 |
| Merck Sharp & Dohme Corp. | Phase 1 |
Pharmacology for betrixaban
| Drug Class | Factor Xa Inhibitor |
| Mechanism of Action | Factor Xa Inhibitors |
Synonyms for betrixaban
| 330942-05-7 |
| 4CA-0269 |
| 74RWP7W0J9 |
| 942B057 |
| AB0027977 |
| AB1008465 |
| ABP000384 |
| AC-30214 |
| AKOS005146070 |
| AN-3565 |
| API0007103 |
| BC638590 |
| BCP01903 |
| BCP9000395 |
| BDBM50249298 |
| Benzamide, N-(5-chloro-2-pyridinyl)-2-((4-((dimethylamino)iminomethyl)benzoyl)amino)-5-methoxy- |
| Betrixaban (USAN) |
| Betrixaban [USAN:INN] |
| betrixaban/ |
| Bevyxxa |
| CHEBI:140421 |
| CHEMBL512351 |
| compound 11 [PMID: 19297154] |
| CS-2481 |
| D08873 |
| DB12364 |
| EX-A358 |
| FT-0663094 |
| GTPL9602 |
| HY-10268 |
| KB-75507 |
| KS-00000645 |
| MolPort-009-682-948 |
| N-(5-Chloro-2-pyridinyl)-2-[[4-[(dimethylamino)iminomethyl]benzoyl]amino]-5-methoxybenzamide |
| N-(5-chloro-2-pyridyl)-2-[[4-(N,N-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxy-benzamide |
| N-(5-Chloropyridin-2-yl)-2-((4-(N,N-dimethylcarbamimidoyl)benzoyl)amino)-5- methoxybenzamide |
| N-(5-chloropyridin-2-yl)-2-({[4-(N,N-dimethylcarbamimidoyl)phenyl]carbonyl}amino)-5-methoxybenzamide |
| N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide |
| N-(5-Chloropyridin-2-yl)-2-[[4-(N,N-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxybenzamide |
| N-(5-chloropyridin-2-yl)-2-[4-(N,N-dimethylcarbamimidoyl)benzamido]-5-methoxybenzamide |
| NCGC00371122-02 |
| PRT 054021 |
| PRT-054021 |
| PRT054021 |
| QCR-99 |
| SB16951 |
| SCHEMBL158591 |
| UNII-74RWP7W0J9 |
| VA11998 |
| W9900 |
| ZINC30691754 |
US Patents and Regulatory Information for betrixaban
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-002 | Jun 23, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-001 | Jun 23, 2017 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-002 | Jun 23, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-001 | Jun 23, 2017 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for betrixaban
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 1390206 | Start Trial |
| South Africa | 200306490 | Start Trial |
| South Korea | 101472765 | Start Trial |
| Germany | 60040676 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.